Literature DB >> 20002300

High levels of circulating N-terminal pro-brain natriuretic peptide in patients with hepatitis C.

A Antonelli1, C Ferri, S M Ferrari, M Colaci, M Sebastiani, A L Zignego, E Ghiri, F Goglia, P Fallahi.   

Abstract

Many patients chronically infected by hepatitis C virus (HCV) experience symptoms like fatigue, dyspnea and reduced physical activity. However, in many patients, these symptoms are not proportional to the liver involvement and could resemble symptoms of chronic heart failure. To our knowledge, no study evaluated serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) in a large series of patients with HCV chronic infection (HCV+). Serum NT-proBNP was assayed in 50 patients HCV+ and in 50 sex- and age-matched controls. HCV+ patients showed significantly higher mean NT-proBNP level than controls (P = 0.001). By defining high NT-proBNP level as a value higher than 125 pg/mL (the single cut-off point for patient under 75 years of age), 34% HCV+ and 6% controls had high NT-proBNP (Fisher exact test; P < 0.001). With a cut-off point of 300 pg/mL (used to rule out chronic heart failure in patients under 75 years of age) 10% HCV+ and 0 controls had high NT-proBNP (Fisher exact test; P = 0.056). With a cut-off point of 900 pg/mL (used for ruling in chronic heart failure in patients with age 50-75) 8% HCV+ patients and 0 controls had high NT-proBNP (Fisher exact test; P = 0.12). The study demonstrates high levels of circulating NT-proBNP in HCV+ patients compared to healthy controls. The increase of NT-proBNP may indicate the presence of a sub-clinical cardiac dysfunction. Further prospective studies quantifying these symptoms in correlation with echocardiography are needed to confirm this association.
© 2009 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20002300     DOI: 10.1111/j.1365-2893.2009.01237.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  8 in total

1.  The differential diagnostic value of serum NT-proBNP in hospitalized patients of heart failure with pneumonia.

Authors:  Shuangshuang Yang; Linbin Li; Ju Cao; Hongsong Yu; Huajian Xu
Journal:  J Clin Lab Anal       Date:  2014-03-28       Impact factor: 2.352

2.  Assessment of cardiac involvement of hepatitis C virus; tissue Doppler imaging and NTproBNP study.

Authors:  Ahmed Saleh; Akira Matsumori; Hany Negm; Hany Fouad; Ahmed Onsy; Mohammed Shalaby; Enas Hamdy
Journal:  J Saudi Heart Assoc       Date:  2011-05-23

3.  Cardiac remodelling identified by cardiovascular magnetic resonance in patients with hepatitis C infection and liver disease.

Authors:  Phillip J Ngu; Michelle Butler; Alan Pham; Stuart K Roberts; Andrew J Taylor
Journal:  Int J Cardiovasc Imaging       Date:  2015-12-15       Impact factor: 2.357

Review 4.  Immunological alterations in hepatitis C virus infection.

Authors:  Vincenza Calvaruso; Antonio Craxì
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

5.  Association between high-sensitivity C-reactive protein and N-Terminal Pro-B-Type Natriuretic Peptide in patients with hepatitis C virus infection.

Authors:  Wenliang Che; Buchun Zhang; Wenling Liu; Yidong Wei; Yawei Xu; Dayi Hu
Journal:  Mediators Inflamm       Date:  2012-05-08       Impact factor: 4.711

6.  An interesting rash: leucocytoclastic vasculitis with type 2 cryoglobulinaemia.

Authors:  Gurdeep Singh Mannu
Journal:  JRSM Short Rep       Date:  2010-11-22

7.  Clinical significance of the long non-coding RNA NEAT1/miR-129-5p axis in the diagnosis and prognosis for patients with chronic heart failure.

Authors:  Haohua Zhang; Nianli Zhang; Wenbin Jiang; Xiaoqin Lun
Journal:  Exp Ther Med       Date:  2021-03-19       Impact factor: 2.751

Review 8.  Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review.

Authors:  Ahmed Babiker; Mohamed Hassan; Safwan Muhammed; Gregory Taylor; Bhawna Poonia; Anoop Shah; Shashwatee Bagchi
Journal:  Clin Cardiol       Date:  2019-11-30       Impact factor: 2.882

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.